Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0STJDA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
aLE.P03
|
|||||
| Synonyms |
ALE.P03
Click to Show/Hide
|
|||||
| Organization |
Alentis Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
H1L1
|
Antibody Info | ||||
| Antigen Name |
Claudin-1 (CLDN1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Biliary tract cancer |
1 Trials
|
||||||||
| Cervical cancer |
1 Trials
|
||||||||
| Colorectal cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Urothelial cancer |
1 Trials
|